[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100560999":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":31,"centralContacts":35,"locations":45,"responsibleParty":77,"collaborators":79,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":39,"eligibilityCriteria":89,"healthyVolunteers":90,"sex":91,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":39,"studyType":97,"phases":98,"briefSummary":100,"conditions":101,"keywords":106,"overallStatus":48,"whyStopped":39,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"Yale University","OTHER",[8,14,17,21],{"label":9,"type":10,"description":11,"interventionNames":12},"Light\u002FNon Drinking (LD)","EXPERIMENTAL","Participants will complete an initial telephone screen. Participants found to be potentially eligible will be scheduled for an in-person Intake Session (consisting of an interview, questionnaires, lab work, and a urine drug screen). Participants found to be eligible will be scheduled for an infusion study. Participants will undergo brain imaging with intravenous administration of deuterated sodium acetate. Deuterium is a naturally occurring, non-radioactive substance that allows us to measure rates of metabolism. Neurocognitive tests will be performed to assess the impact of alcohol drinking.",[13],"Other: Deuterium Metabolic Imaging with deuterated acetate tracer",{"label":15,"type":10,"description":11,"interventionNames":16},"Heavy\u002FNon-Dependent Risky Drinking (HD)",[13],{"label":18,"type":10,"description":19,"interventionNames":20},"Treatment Seeking (TS)","Participants will complete an initial telephone screen. Participants to be potentially eligible will be scheduled for an in-person Intake Session (consisting of an interview, questionnaires, lab work, and a urine drug screen). If found to be eligible participants will be scheduled for an inpatient admission. Participants will take part in an inpatient, medically supervised detoxification. In early sobriety (normally within one week of the last drink) and after approximately one month, participants will undergo brain imaging with intravenous administration of deuterated sodium acetate. Deuterium is a naturally occurring, non-radioactive substance that allows us to measure rates of metabolism. Neurocognitive tests will be performed to assess the impact of alcohol drinking.",[13],{"label":22,"type":10,"description":11,"interventionNames":23},"Long-Term Recovery (LTS)",[13],[25],{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"Deuterium Metabolic Imaging with deuterated acetate tracer","Deuterium Metabolic Imaging (DMI) is a method by which Magnetic Resonance Spectroscopy (MRS) is used to map the appearance of deuterium from a tracer source (e.g., deuterated acetate) in products of metabolism. In this case we will map the combination of glutamate and glutamine, called Glx, to serve as a tag to measure the brain's rate of acetate consumption. That is, the more deuterium appears in Glx, the more acetate that part of the brain consumes.",[15,9,22,18],[30],"DMI",[32],{"name":33,"affiliation":5,"role":34},"Graeme Mason, Ph.D.","PRINCIPAL_INVESTIGATOR",[36,41],{"name":33,"role":37,"phone":38,"phoneExt":39,"email":40},"CONTACT","203-737-1478",null,"graeme.mason@yale.edu",{"name":42,"role":37,"phone":43,"phoneExt":39,"email":44},"Luz Catarineau","475-375-6141","luz.catarineau@yale.edu",[46,66],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"The Anlyan Center, 300 Cedar St.","RECRUITING","New Haven","Connecticut","06519","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-72.92816,41.30815,{"lat":58,"lon":57},[61,64],{"name":62,"role":37,"phone":43,"phoneExt":39,"email":63},"Elizabeth Guidone, BA","Elizabeth.Guidone@yale.edu",{"name":65,"role":34,"phone":39,"phoneExt":39,"email":39},"Graeme Mason, Ph.D",{"facility":5,"status":67,"city":49,"state":50,"zip":68,"country":52,"countryCode":53,"cosmosGeoPoint":69,"geoPoint":71,"contacts":72},"NOT_YET_RECRUITING","06520",{"type":55,"coordinates":70},[57,58],{"lat":58,"lon":57},[73,74],{"name":33,"role":37,"phone":38,"phoneExt":39,"email":40},{"name":75,"role":37,"phone":43,"phoneExt":39,"email":76},"Elizabeth Guidone, B.A.","elizabeth.guidone@yale.edu",{"type":78,"investigatorFullName":39,"investigatorTitle":39,"investigatorAffiliation":39,"oldNameTitle":39,"oldOrganization":39},"SPONSOR",[80],{"name":81,"class":82},"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","NIH","100560999","drinking-acetate-and-stress-100560999",false,"NCT06584448","Drinking, Acetate, and Stress","Role of Acetate in Heavy Drinking","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Medically stable male or female, aged 18-55.\n* Able to read, write and complete a multitude of self-assessments in English\n* Meets DSM-5 criteria for current Alcohol Use Disorder (AUD)\n* Participants who have Alcohol Use Disorder and are actively drinking must be willing to receive (at no cost) inpatient treatment for AUD for a period of up to 30 days. Participants who have been treated for an Alcohol Use Disorder and are now sober three months or longer will NOT be required to go inpatient.\n\nExclusion Criteria:\n\n* Subjects with any significant current medical conditions (neurological, cardiovascular, endocrine, thyroid, renal, liver), seizures (for LTS subjects only- seizures directly related to alcohol detoxification are not an exclusion) , delirium or hallucinations, or other unstable medical conditions, including HIV.\n* Current DSM-5 substance use disorder (other than AUD or tobacco use disorder)\n* Any metallic objects implanted in their body which would make imaging unsafe (pacemaker, etc)\n* Claustrophobia, or other inability to participate in an MRI\n* A positive test result at intake appointment and subsequent appointments on urine drug screens conducted for illicit drugs. (Note: participants will not be paid for study visits if they test positive for an illicit drug and will be immediately excluded from study).\n* Women who are pregnant or nursing. Women who have an IUD that would make imaging unsafe.\n* Recent taking of medications that may influence study outcomes (e.g., disulfiram, naltrexone, acamprosate, anticonvulsants).\n* Subjects likely to exhibit clinically significant alcohol withdrawal during the study.",true,"ALL","18 Years","55 Years",{"count":95,"type":96},50,"ESTIMATED","INTERVENTIONAL",[99],"NA","The purpose of this study is to learn how drinking alcohol affects how people experience stress and how that is affected by the body's chemistry. Specifically, the investigators will be studying relationships of drinking and a stress hormone called cortisol. The investigators believe that results will lead us to find more effective ways to help people stop or reduce drinking when participants are drinking at harmful levels.",[102,103,104,105],"Alcohol Use Disorder","Alcohol Use, Unspecified","Heavy Drinker","Alcohol Use Disorder, Moderate, in Sustained Remission",[107,108,109,110,111,112],"Brain","Stress","Imaging","Detoxification","Recovery","Sobriety","2026-06-11",{"date":115,"type":116},"2026-06-15","ACTUAL",{"date":118,"type":116},"2024-11-06",{"date":120,"type":96},"2030-01",{"name":5,"class":6},2]